A 58-Year-Old Man With Hemoptysis After COVID-19 Infection.

Area of Science:

• Infectious Diseases
• Pulmonology
• Pharmacology

Background:

• A 58-year-old male with a history of well-controlled asthma presented with acute respiratory symptoms.
• The patient had recently recovered from a COVID-19 infection requiring hospitalization and treatment.

Observation:

• The patient received a 5-day course of remdesivir and a 3-week course of dexamethasone for COVID-19.
• The dexamethasone dosage was high (12 mg twice daily for 14 days) and then tapered.
• Symptoms included high-grade fever and progressive dry cough starting one week prior to presentation.

Findings:

• The patient developed significant fever and cough four weeks after the initial COVID-19 diagnosis.
• The clinical presentation suggests a potential complication or secondary effect related to the prior COVID-19 treatment, particularly the high-dose, prolonged dexamethasone course.

Implications:

• This case underscores the importance of monitoring for delayed adverse effects following high-dose corticosteroid treatment in post-COVID-19 patients.
• Further investigation into the relationship between intensive immunosuppressive therapy and subsequent respiratory symptoms is warranted.
• Clinicians should consider prolonged corticosteroid use as a potential factor in post-viral respiratory sequelae.